Flow cytometry-based cytotoxicity and antibody binding assay.
Flow cytometry-based cytotoxicity and antibody binding assay.
Curr Protoc Cytom. 2013;66:Unit 6.34.
Authors: Alheim M
Abstract
Human leukocyte antigen (HLA) antibodies with the ability to activate complement are associated with an increased risk of early antibody-mediated graft rejection in kidney transplantation (KTx). Detection of these potentially harmful complement-fixing HLA antibodies is commonly performed via the complement-dependent cytotoxicity (CDC) assay according to protocols that were developed as early as 40 years ago. The read-out for this assay is based on manual scoring by visual inspection of cells under a fluorescence microscope. CDC is often used in combination with the flow cytometry-based lymphocyte crossmatch assay (FCXM), which, with high sensitivity, detects HLA antibody binding. Here we describe a new approach wherein both cytotoxicity and antibody binding can be simultaneously assessed with flow cytometry. Two strategies are described, using either magnetic bead-enriched T and B lymphocytes or bulk peripheral blood mononuclear cells (PBMC) as donor target cells.
PMID: 24510725 [PubMed - indexed for MEDLINE]
Source: Current Protocols in Cytometry - Category: Molecular Biology Tags: Curr Protoc Cytom Source Type: research
More News: Kidney Transplant | Kidney Transplantation | Molecular Biology | Transplants | Urology & Nephrology